☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Breast Cancer
Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Ca...
February 2, 2022
Eli Lilly's Verzenio (abemaciclib) Receives the US FDA's Approval for People with HR+ HER2- High Risk Early Breast Cancer
October 13, 2021
PharmaShots Interview: Q BioMed's Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affa...
July 13, 2021
PharmaShots Interview: Daiichi Sankyo's Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Canc...
June 2, 2021
Zydus Cadila Launches Ujvira (biosimilar- trastuzumab emtansine) for Early and Advanced HER2 Positive Breast Cancer
May 24, 2021
Boehringer Ingelheim to Acquires NBE-Therapeutics ~ $1.5B
December 11, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.